EP3925607
Lyfjasamsetningar til meðhöndlunar á slímseigjusjúkdóms-himnuleiðnistillis-miðluðum sjúkdómum
:
EP einkaleyfi í gildi á Íslandi:
14.4.2015:
28.6.2023:
21175519.4
:
28.8.2023:
15.9.2023
:
13.4.2035:
13.4.2026:
30.4.2026
:
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES
14.4.2015
28.6.2023
28.8.2023
15.9.2023
13.4.2026
:
Vertex Pharmaceuticals Incorporated:
50 Northern Avenue, Boston, MA 02210, US
:
PHENIX, Brian Dean:
Acton 01720, US
:
BAGNOL, Laurent Jean-claude:
Burlington 01803, US
:
BRODEUR, Geoffrey Glen:
Boston 02210, US
:
CHANDRAN, Sachin:
Somerville 02144, US
:
DOKOU, Eleni:
Cambridge 02140, US
:
FERRIS, Lori Ann:
Medford 02155, US
:
KNEZIC, Dragutin:
Watertown 02472, US
:
MCCARTY, Katie Lynn:
Watertown 02472, US
:
MEDEK, Ales:
Winchester 01890, US
:
WAGGENER, Sara A.:
N. Billerica 01862, US
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
201461979848 P:
15.4.2014:
US
:
201462059287 P:
3.10.2014:
US
:
A61K 31/404, A61K 9/14, C07D 209/04, C07D 215/00, A61K 45/06, A61K 9/20, A61K 31/47, A61K 9/16, A61P 11/00
: 10
: 19.3.2024
: 13.4.2025
: Árnason Faktor ehf.
: 11
: 14.4.2025
: 13.4.2026
: Árnason Faktor ehf.